Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Aliskiren in high-risk type 2 diabetes
jRCT2080220554Phase 3
- Sponsor
- Novartis
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of aliskiren in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), coronary arteriosclerosis and 3 more, sponsored by Novartis.
02
Drugs
aliskiren
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)coronary arteriosclerosisheart failure (HF)myocardial infarction (MI)
Beyond the preview
Go deeper on jRCT2080220554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220554.